Health
US presses India to resume Covid-19 vaccine export
WASHINGTON: The Biden administration has been pressing Prime Minister Narendra Modi reportedly to let India resume exporting Covid-19 vaccines, and is tying it to a possible prominent role for him at a global summit US President Joe Biden plans to hold on the sidelines of the UN general assembly meetings.
“We have regularly been communicating with (the) government of India in bilateral and multilateral channels to discuss vaccine supply and inquire about the timeline for exports,” a US official said, insisting, at the same time, that “these conversations are not tied to a specific summit or engagement,”.
Prime Minister Modi’s participation in the summit will not be incumbent upon his agreeing to resume the export of vaccines. The summit has not been announced yet.
Prime Minister Modi will be joining his counterparts from Australia and Japan Scott Morrison and Yoshihide Suga and President Biden for the first in-person summit of the Quad here at the White House on September 24, according to announcements by the ministry and external affairs and the White House. And the pandemic is on the agenda, along with climate change and the Indo-Pacific.
India ceased export of Covid-19 vaccines earlier in the year after it faced internal criticism for not inoculating enough Indians locally in the wake of a massive surge in cases caused by the more virulent Delta variant.
Health
Expert Advice On COVID Vaccination For Children
Mansukh Mandaviya, the Union Health Minister, announced on Saturday that the central government will begin administering COVID-19 immunisation to children aged 5 to 15 years as soon as a group of specialists makes recommendations to that effect.
When asked about the government’s immunisation policy for youngsters aged 5 to 15, Mandaviya addressed reporters in this city.
He stated that the expert panel has yet to make a recommendation about this category’s vaccination.
The minister was in town for a BJP-hosted event on the Union Budget, which was announced on February 1.
“A panel of scientists recommends when and how to vaccinate, as well as which age groups to vaccinate. Within one week, we had implemented the precaution group’s advice. We will undoubtedly put its advice (for the age group of 5 to 15) into action as soon as we receive it “During a press conference, he stated.
COVID-19 immunisation for children aged 15 to 18 years old began last month across the country.
“Vaccination is no longer a concern. There is no shortage of vaccines; there are no shortages of dosages. We will unquestionably accept the scientific community’s advice “Mandaviya threw in her two cents.
The ministry has yet to receive such a suggestion and will make a decision in the following days based on that information. It isn’t a decision based on politics. In July-August of last year, he noted, a serosurvey and seroprevalence study revealed that 67% of youngsters developed antibodies while remaining asymptomatic.
“In the end, it’s all about biology. As a result, before making recommendations, scientists do research. We used to watch the news all the time (for recommendations regarding vaccination). Our scientists today perform their research, conduct their studies, and form their conclusions “He expressed himself.
He further said that during the third wave of the pandemic, India employed immunisation to combat it quite efficiently.
The minister stated that large-scale immunisation helped India combat the third wave, as evidenced by leading institutes around the world and the Indian Council of Medical Research (ICMR).
According to him, 75% of children (15-18 years old) have had their COVID-19 immunisation shots, 96% of adults have received the first dose, and 77% have received both doses.
“Based on all of this, I can certainly say that India has been able to use vaccination very effectively to fight against the COVID-19 crisis,” he said, adding that the ICMR studies showed that COVID-19 vaccination has helped the majority of people, and as a result, the country is moving toward the flattening of the curve.
He claimed that the government’s focus on vaccination during the 2020 shutdown, which began shortly after the virus’s emergence, helped India maintain its economic economy and avoid the high inflation and negative growth witnessed in the United States and Europe.
According to Mandaviya, vaccination research was prioritised by the government, and the government provided funding for it. By January 16 of last year, India’s indigenously manufactured vaccine had been launched at the same time as vaccines created in other countries.
“India made immunisation available to the rest of the globe and even began mass-producing it. As a result, when the third wave (of the COVID-19 pandemic) arrived, we were already ahead of the game in terms of immunisation. Because India had completed 96 per cent of the first dose, we were spared in the third wave “He expressed himself.
Mandaviya, speaking about the Union Budget, said that India would enter a golden period.
“I am confident that its implementation will accelerate comprehensive and time-bound development in the correct direction,” he said.
Health
Chinese scientists inform about yet another type of Coronavirus
According to a new study by Chinese researchers, a new type of coronavirus named NeoCov, that spreads among bats may pose a threat to humans in the future if it mutates further.
The study that was recently posted on the preprint repository BioRxiv shows that NeoCov is closely related to the Middle East respiratory syndrome (MERS), a viral disease first identified in Saudi Arabia in 2012.
Coronaviruses are a large family of viruses that can cause diseases ranging from the common cold to Severe Acute Respiratory Syndrome (SARS).
Researchers from the Chinese Academy of Sciences and Wuhan University noted that NeoCov is found in a population of bats and to date spreads exclusively among these animals.
In its current form, NeoCov does not infect humans but further mutations may make it potentially harmful for human life. The researchers further noted that infection with NeoCov could not be cross-neutralised by antibodies targeting the existing variants of coronavirus.
Health
Covid vaccines like Covaxin, Covishield to be available in hospitals
Covaxin and Covishield will now be available in the regular market as the Drug Controller General of India have given conditional market approval to these two Covid vaccines on Thursday.
The subject expert committee of the Central Drug Standard Control Organisation has earlier recommended granting regular market approval to these Covid-19 vaccines for the adult population, subject to certain conditions. Market approval, however, does not mean that the vaccines will be available in medical shops. People will have to buy Covishield and Covaxin from hospitals and clinics.
Vaccination data has to be submitted to DCGI every six months. Data will have t to be updated on CoWIN app also. Earlier, it was reported that the Centre was planning to cap the price of the vaccines at ₹275 per dose.
The approval has been granted under the New Drugs and Clinical Trials Rules, 2019. The firms, in this case, Bharat Biotech (Covaxin) and Serum Institute of India (Covishield), shall submit data of ongoing clinical trials
All vaccination data will be recorded on the CoWIN platform. The approval is only for adult population.
-
India2 years ago
As the arrangement with Prashant Kishor falls through Rahul Gandhi has gone overseas again and is uncontactable
-
Fact Check4 years ago
Nidhi Razdan, fake Harvard professorship, and here is the explanation through her blog.
-
Latest News3 years ago
Tata wins Air India with ₹18,000 crore bid
-
Technology3 years ago
BSNL reveals all new 4G plans starting at ₹16
-
Latest News3 years ago
Government has spent ₹9,725 crores on Covid-19 vaccination drive so far
-
Latest News3 years ago
Jharkhand government cuts Petrol price by massive ₹25 a litre but with a catch
-
Navi Mumbai3 years ago
Navi Mumbai civic body raids and tests morning walkers, many found COVID positive
-
Latest News3 years ago
Raj Kundra Gave ₹25 Lakh Bribe to Mumbai Crime Branch to Avoid Arrest